CEO Yen Wen Pin’s IPO Vision Gains Traction as OncoX Expands Pipeline
SILICON VALLEY, CA - August 1, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today shared a strategic update on its ongoing collaboration with OncoX BioPharma, Inc., a rising oncology player that has licensed four IND-stage drug assets from ABVC. The two companies have taken another step forward, as OncoX continues to unlock funding to support product advancement under its bold, innovation-driven roadmap.
Led by its CEO, Mr. Yen Wen Pin, OncoX has leveraged its core competencies in natural product innovation and dietary supplements to build a unique position in oncology. The Company is actively translating its strengths into a pipeline of immunotherapy-driven treatments supported by ABVC’s IND-stage programs. Mr. Yen’s strategic vision includes building long-term revenue streams through therapeutic innovation and cross-sector expansion.
“We are building OncoX with a long-term vision to deliver real value to patients and investors,” said Mr. Yen Wen Pin, CEO of OncoX BioPharma. “Through the licensed INDs from ABVC and continued collaboration, we’re pushing forward innovative therapies that will anchor our strategy and will help facilitate our momentum, stability, and strong identity in the cancer therapeutics space.”
OncoX’s platform centers around immunotherapy-inspired cancer treatments derived from ABVC’s clinical-stage portfolio. Each program represents a carefully selected opportunity - designed not for the sake of headlines, but for real progress. OncoX has deliberately raised capital in phases, allocating it directly to the development of these candidates. Its recent funding efforts have led to the fulfillment of an additional milestone payment, a sign of both operational discipline and intent.
“We view this partnership as a case study in how smart biotech collaborations can grow over time,” said Dr. Uttam Patil, ABVC's Chief Executive Officer. “OncoX’s consistent execution has translated into steady licensing revenue for ABVC and increasing momentum around these oncology programs. We’re optimistic about what the next chapters will bring.”
Including this latest milestone, ABVC and its subsidiaries have now recorded a total of $1.396 million in cumulative licensing income from OncoX and other strategic partners, including AiBtl BioPharma and ForSeeCon Eye Corporation.
With each step forward, OncoX brings new definition to its roadmap - blending innovation with pragmatism, and aligning business development efforts with the scientific potential of its pipeline. OncoX remains focused on developing not only drug candidates, but a revenue-generating model grounded in credibility and commercial viability.
About OncoX BioPharma
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company currently has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has demonstrated promising safety and efficacy in early-phase clinical studies and received four INDs (Investigational New Drug Applications) approved by the U.S. FDA. The Company believes that the estimated total market opportunity of its oncology pipeline, inclusive of its existing licensing agreements and assets, is significant.
In addition to its therapeutic pipeline, OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. The company has also acquired the Lycogen® extraction platform to enter adjacent fields including preventative medicine, chronic disease care (such as benign prostatic hyperplasia, diabetic wound healing), aesthetic medicine, and animal health. These cross-sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research.[1]
OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility. The company is expanding its global footprint, with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets. OncoX is currently preparing for future clinical milestones and pursuing long-term international partnerships to bring its innovative therapies to patients worldwide.
[1] https://www.prnewswire.com/news-releases/lycopene-market-to-reach-187-3-million-globally-by-2030-at-5-2-cagr-allied-market-research-301371075.html?utm_source=chatgpt.com
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Uttam Patil
Email: uttam@ambrivis.com
